Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06289673 · ClinicalTrials.gov registry record · Phase 4
Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma
A Phase 4 study of Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia, sponsored by St. Jude Children's Research Hospital.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 850
- Enrollment target
- 3
- Study locations
NCT06289673 is a Phase 4 study of Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia that is actively recruiting participants, run by St. Jude Children's Research Hospital. The registered enrollment target is 850 participants, above the 376-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (126% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT06289673, a Phase 4 study of Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia, is actively recruiting participants, sponsored by St. Jude Children's Research Hospital.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 850 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * To provide sufficient therapy to enable testing of newly diagnosed acute lymphoblastic leukemia/lymphoma and mixed phenotype acute leukemia/lymphoma tumor samples to determine eligibility and appropriate risk stratification for SJALL therapeutic studies. * To develop a central database of genomic and clinical findings. Secondary Objectives * To assess event free and overall survival data of patients enrolled on this study.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Vincristine
- DRUG Daunorubicin
- DRUG Methotrexate
- DRUG Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Study Locations (3)
California
- Rady Children's Hospital - San Diego
Oklahoma
- Saint Francis Children's Hospital - Tulsa
Tennessee
- St. Jude Children's Research Hospital - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 850 participants |
| Start Date | 2024-12-26 |
| Est. Completion | 2039-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06289673
The ClinicalTrials.gov registry entry for NCT06289673 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 850 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 376-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (126% higher). The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.
NCT06289673 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Oklahoma, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06289673 about?
NCT06289673 is a clinical study titled "Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma". The goal of this study is to provide sufficient therapy during the time a patients' B-cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy) risk category is being determined. The term "risk" refers to the chance of the ALL or LLy coming back after treatment. Primary Objectives * ...
What is the current status of trial NCT06289673?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 850 participants. The study started on 2024-12-26. Estimated completion is 2039-05.
What conditions does trial NCT06289673 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, Lymphoblastic Lymphoma.
What interventions are being tested in trial NCT06289673?
The interventions under investigation include: Dexamethasone (DRUG), Vincristine (DRUG), Daunorubicin (DRUG), Methotrexate (DRUG), Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine) (DRUG).
Who is sponsoring clinical trial NCT06289673?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06289673 being conducted?
This trial has 3 study locations across California, Oklahoma, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
RECRUITING
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
RECRUITING · Phase 1
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RECRUITING · Phase 1
Explore more on PlainTrial
Acute Lymphoblastic Leukemia
All registered trials for this condition
Mixed Phenotype Acute Leukemia
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.